Filing Flows › Zymeworks (ZYME) › Guidance & outlook
Zymeworks (ZYME) guidance and outlook
Zymeworks' 10-Q filed Nov 9, 2026 makes 52 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 9, 2026
- Other than the receipt of royalties on sales of zanidatamab and potential regulatory milestone payments relating to future regulatory approvals of zanidatamab, we expect to generate revenue related to the sale of approved products and other commercial activities, including through our acquisition of Theravance Biopharma, Inc.
- We also expect to continue to receive royalties and milestone payments from existing and future strategic partners.
- Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our existing cash and cash equivalents as of September 30, 2026, together with the $250.0 million Jazz milestone payment received in October 2026, will enable us to fund our operating expenditures and capital expenditure requirements for at least the next twelve months from the date this…
- We anticipate that while we will be profitable for 2026, at least over the near to medium
- term we will not be consistently profitable on a quarterly basis as we execute our strategic plan announced in 2025, which emphasizes disciplined capital allocation, focused research and development investment, advancement of partnered programs, and active management of our royalty and asset portfolio.
- Our operating expense outlook reflects a multi-year planning framework designed to align spending with defined strategic priorities, including pipeline progression, technology platform advancement, and value-enhancing business development activities.
- We are prioritizing investments where we believe risk-adjusted returns are most attractive and expect operating expenses to be managed within this structured framework.
- Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and internal innovation, supported by disciplined capital allocation and a strengthened financial foundation through expected milestone payments and royalties from existing commercial partners.
- As partnered therapies advance through late-stage development and commercialization, we expect to grow durable and predictable cash flows that can be deployed by us in order to seek attractive risk-adjusted returns for stockholders.
- We intend to evaluate and selectively acquire programs, technologies, product candidates and/or companies with high-quality assets or partnerships that align with our strategic objectives.
- Decisions regarding capital returns are evaluated within the context of our liquidity position, future cash flow outlook, and overall strategic objectives.
- We also expect that royalty revenue from Ziihera sales will increase as potential additional regulatory approvals are obtained in global markets for GEA.
Zymeworks' latest quarter
Zymeworks, Q3 2026: revenue $256M (+829% year over year), operating margin 69.2%, net earnings $174M, operating cash flow −$24.0M. The chart follows the revenue to costs, profit and cash.
Questions
What does Zymeworks expect?
Other than the receipt of royalties on sales of zanidatamab and potential regulatory milestone payments relating to future regulatory approvals of zanidatamab, we expect to generate revenue related to the sale of approved products and other commercial activities, including through our acquisition of Theravance Biopharma, Inc. We also expect to continue to receive royalties and milestone payments from existing and future strategic partners. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our existing cash and cash equivalen
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.